Table 1 Demographics and clinical parameters of the study population
Days after RT-PCR confirmation | 15–30 days | 31–60 days | 61–90 days | 91–120 days | 121–150 days | 151–180 days | More than 180 days |
|---|---|---|---|---|---|---|---|
Subjects enrolled | n = 46 | n = 33 | n = 38 | n = 34 | n = 32 | n = 37 | n = 40 |
Median age (range) | 41.5 (18–70) | 36 (25–68) | 45 (19–59) | 45 (21–69) | 45.5 (27–59) | 42 (23–58) | 38.5 (21–78) |
Gender (M/F) | 27/19 | 17/18 | 22/15 | 22/12 | 14/18 | 23/16 | 26/14 |
Fever, no. (%) | 29 (67%) | 22 (65%) | 28 (74%) | 23 (74%) | 25 (83%) | 23 (72%) | 17 (47%) |
Chills, no. (%) | 9 (21%) | 5 (15%) | 2 (5%) | 7 (22%) | 4 (13%) | 1 (3%) | 3 (8%) |
Cough, no. (%) | 21 (49%) | 20 (59%) | 14 (37%) | 15 (48%) | 14 (47%) | 17 (53%) | 12 (33%) |
Sore throat, no. (%) | 21 (49%) | 12 (35%) | 11 (29%) | 12 (38%) | 10 (33%) | 16 (50%) | 13 (36%) |
Runny nose, no. (%) | 7 (16%) | 6 (18%) | 5 (13%) | 0 | 3 (10%) | 6 (19%) | 5 (14%) |
Taste loss, no. (%) | 24 (55%) | 14 (41%) | 17 (44%) | 12 (39%) | 11 (37%) | 20 (63%) | 12 (33%) |
Smell loss, no. (%) | 21 (49%) | 14 (41%) | 21 (55%) | 9 (29%) | 11 (37%) | 16 (50%) | 10 (28%) |
Muscle aches, no. (%) | 23 (53%) | 20 (59%) | 29 (76%) | 15 (48%) | 18 (60%) | 21 (66%) | 13 (36%) |
Joint pain, no. (%) | 21 (49%) | 18 (53%) | 20 (53%) | 10 (32%) | 18 (60%) | 14 (44%) | 9 (25%) |
Abdominal pain, no. (%) | 3 (7%) | 3 (9%) | 4 (11%) | 2 (6.5%) | 3 (10%) | 2 (7%) | 3 (8%) |
Vomit, no. (%) | 3 (7%) | 4 (12%) | 5 (13%) | 4 (13%) | 3 (10%) | 5 (16%) | 3 (8%) |
Diarrhea, no. (%) | 10 (23%) | 5 (15%) | 4 (11%) | 4 (13%) | 6 (30%) | 5 (16%) | 2 (6%) |
Seizures, no. (%) | 0 | 1 (3%) | 0 | 0 | 0 | 0 | 0 |
Hypertension, no. (%) | 11 (26%) | 7 (21%) | 7 (18%) | 7 (23%) | 9 (30%) | 9 (28%) | 8 (22%) |
Diabetes, no. (%) | 8 (19%) | 7 (21%) | 11 (30%) | 9 (29%) | 11 (37%) | 8 (25%) | 7 (19%) |
Asthma, no. (%) | 2 (5%) | 2 (6%) | 1 (3%) | 1 ( 3%) | 0 | 1 (3%) | 0 |
Chronic kidney disease, no. (%) | 0 | 0 | 0 | 0 | 1 (3%) | 0 | 1 (3%) |
Neuro, no. (%) | 0 | 0 | 2 (5%) | 0 | 0 | 0 | 0 |
Cancer, no. (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Heart, no. (%) | 1 (6%) | 2 (3%) | 1 (3%) | 0 | 0 | 1 (3%) | 0 |
Rheumatic fever, no. (%) | 0 | 0 | 1 (3%) | 0 | 0 | 1 (3%) | 0 |
Corticosteroids, no. (%) | 4 (9%) | 3 ( 9%) | 2 (5%) | 3 (10%) | 1 (3%) | 1 (3%) | 0 |
Antiviral drug, no. (%) | 4 (9%) | 5 (15%) | 2 (5%) | 4 (13%) | 0 | 0 | 0 |
Immunomodulator, no. (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |